A New Therapeutic Approach for Brain Delivery of Epigallocatechin Gallate: Development and Characterization Studies.
Animals
Behavior, Animal
/ drug effects
Biological Availability
Blood-Brain Barrier
/ drug effects
Catechin
/ analogs & derivatives
Cerebral Infarction
/ drug therapy
Disease Models, Animal
Drug Compounding
/ methods
Drug Liberation
Emulsions
Humans
Lipids
/ chemistry
Male
Memory Disorders
/ drug therapy
Mice
Nanoparticles
/ chemistry
Neuroprotective Agents
/ pharmacology
Treatment Outcome
EGCG
brain
ischemia
memory
nanoparticles
neurobehaviour
stroke.
Journal
Current drug delivery
ISSN: 1875-5704
Titre abrégé: Curr Drug Deliv
Pays: United Arab Emirates
ID NLM: 101208455
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
11
2017
revised:
06
04
2018
accepted:
14
09
2018
pubmed:
27
9
2018
medline:
6
4
2019
entrez:
27
9
2018
Statut:
ppublish
Résumé
Blood-brain permeability is the primary concern when dealing with the biodistribution of drugs to the brain in neurological diseases. The purpose of the study is to develop the nanoformulation of Epigallocatechin gallate (EGCG) in order to improve its bioavailability and penetration into the brain. EGCG loaded Solid Lipid Nanoparticles (SLNs) have been developed using microemulsification method and pharmacological assessments were performed. Surface morphology and micromeritics analysis showed the successful development of EGCG loaded solid lipid nanoparticles with an average size of 162.4 nm and spherical in shape. In vitro release studies indicated a consistent and slow drug release. Pharmacological evaluation of SLN-EGCG demonstrated a significant improvement in cerebral ischemia-induced memory impairment. The results indicate that the EGCG loaded SLNs provide a potential drug delivery system for improved delivery of EGCG to the brain, hence, enhancing its brain bioavailability.
Sections du résumé
BACKGROUND
BACKGROUND
Blood-brain permeability is the primary concern when dealing with the biodistribution of drugs to the brain in neurological diseases.
OBJECTIVE
OBJECTIVE
The purpose of the study is to develop the nanoformulation of Epigallocatechin gallate (EGCG) in order to improve its bioavailability and penetration into the brain.
METHODS
METHODS
EGCG loaded Solid Lipid Nanoparticles (SLNs) have been developed using microemulsification method and pharmacological assessments were performed.
RESULTS
RESULTS
Surface morphology and micromeritics analysis showed the successful development of EGCG loaded solid lipid nanoparticles with an average size of 162.4 nm and spherical in shape. In vitro release studies indicated a consistent and slow drug release. Pharmacological evaluation of SLN-EGCG demonstrated a significant improvement in cerebral ischemia-induced memory impairment.
CONCLUSION
CONCLUSIONS
The results indicate that the EGCG loaded SLNs provide a potential drug delivery system for improved delivery of EGCG to the brain, hence, enhancing its brain bioavailability.
Identifiants
pubmed: 30255756
pii: CDD-EPUB-93251
doi: 10.2174/1567201815666180926121104
doi:
Substances chimiques
Emulsions
0
Lipids
0
Neuroprotective Agents
0
Catechin
8R1V1STN48
epigallocatechin gallate
BQM438CTEL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-65Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.